Venus forays into Singapore’s topical pain management market

Venus Remedies has entered into Singapore’s topical pain management market with a marketing authorization and patent for its herbal nanotechnology based pain reliever Trois. The company is holding talks with various pharmaceutical firms for tie-ups to market Trois in Singapore.

It is a great opportunity for the company to capture a sizeable share in this segment of the Singapore pharma market. Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffers from symptoms of osteoarthritis.

Trois is the safest known topical product for management of pain and inflammation associated with rheumatic disorders. It is 30% more effective than conventional products, as proven through a series of toxicity and safety studies. It has 150% enhanced retention for longer effect, improved relief and better mobility

Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.